India: Covaxin and Covishield vaccines invoke 50% fewer antibodies against B.1.617 coronavirus variant

Scientists at the Indian National Institute of Virology (NIV), Pune, have found that both Covaxin and Covishield produce half as many antibodies against the B.1.617 variant of the novel coronavirus as against the ‘original’ B.1 variant.  More...

Europe: EMA assessing reports of Guillain-Barre syndrome with AstraZeneca’s coronavirus vaccine VaxZevria

“As part of the review of the regular pandemic summary safety reports for Vaxzevria, AstraZeneca’s Covid-19 vaccine, the PRAC is analysing data provided by the marketing authorisation holder on cases of Guillain-Barre syndrome (GBS) [1] reported following vaccination.  More...